DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
TEW-7197 is an investigational drug.
There have been 12 clinical trials for TEW-7197. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2021.
The most common disease conditions in clinical trials are Adenocarcinoma, Pancreatic Neoplasms, and Stomach Neoplasms. The leading clinical trial sponsors are MedPacto, Inc., AstraZeneca, and Samsung Medical Center.
There are two US patents protecting this investigational drug and thirty-two international patents.
Recent Clinical Trials for TEW-7197
|Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition||AstraZeneca||Phase 2|
|Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition||MedPacto, Inc.||Phase 2|
|As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers||Samsung Medical Center||Phase 2|
Top disease conditions for TEW-7197
Top clinical trial sponsors for TEW-7197
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|TEW-7197||⤷ Try it Free||1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same||Frequency Therapeutics, Inc. (Woburn, MA)||⤷ Try it Free|
|TEW-7197||⤷ Try it Free||Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance||CHILDREN'S MEDICAL CENTER CORPORATION (Boston, MA) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|TEW-7197||European Patent Office||EP3313420||2035-06-25||⤷ Try it Free|
|TEW-7197||Japan||JP2018519298||2035-06-25||⤷ Try it Free|
|TEW-7197||World Intellectual Property Organization (WIPO)||WO2016210292||2035-06-25||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|